Clinical Potential of HER2 PET as a Predictive Biomarker to Guide the Use of Trastuzumab Deruxtecan in Breast Cancer Patients
Romain‐David Seban, Laurence Champion, Audrey Bellesœur, Anne Vincent‐Salomon, François‐Clément Bidard
Abstract
TO THE EDITOR: We have read with great interest the results of the DESTINY-Breast04 trial, “Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer,” from Modi et al. and published in The New England Journal of Medicine ([1][1]). These impressive findings have also earned a
Topics & Concepts
TrastuzumabBreast cancerMedicineOncologyBiomarkerInternal medicineCancerMedical physicsBiochemistryChemistryHER2/EGFR in Cancer ResearchCancer Treatment and PharmacologyBreast Cancer Treatment Studies